

#6



PATENT
Docket No. 252312005704

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Stephen M. COUTTS et al.

Serial No.: 09/752,533

Filing Date: December 29, 2000

For: CONJUGATES OF CHEMICALLY
DEFINED NON-POLYMERIC
VALENCY PLATFORM MOLECULES
AND BIOLOGICALLY ACTIVE
MOLECULES (AS AMENDED)

Examiner: To Be Assigned

Group Art Unit: 1653

RECEIVED

AUG 01 2001

TECH CENTER 1600/2900

**PROSECUTION BY ASSIGNEE AND POWER OF ATTORNEY
UNDER 37 C.F.R. § 3.71**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

La Jolla Pharmaceutical Company, the assignee of the entire right, title and interest in this patent application, under 37 C.F.R. § 3.71 hereby appoints:

Randolph Ted Apple (Reg No. 36,429)
Sanjay S. Bagade (Reg No. 42,280)
Erwin J. Basinski (Reg No. 34,773)
Richard R. Batt (Reg No. 43,485)
Vincent J. Belusko (Reg No. 30,820)
Kimberly A. Bolin (Reg No. 44,546)
Tyler S. Brown (Reg No. 36,465)
A. Randall Camacho (Reg No. 46,595)
Robert K. Cerpa (Reg No. 39,933)
Alex Chartove (Reg No. 31,942)
Thomas E. Ciotti (Reg No. 21,013)
Matthew M. D'Amore (Reg No. 42,457)
Peter Davis (Reg No. 36,119)
Carolyn A. Favorito (Reg No. 39,183)
Hector Gallegos (Reg No. 40,614)

Laurie A. Axford (Reg No. 35,053)
Joseph Barrera (Reg No. 44,522)
Shantanu Basu (Reg No. 43,318)
Frank P. Becking (Reg No. 42,309)
Jonathan Bockman (Reg No. 45,640)
Barry E. Bretschneider (Reg No. 28,055)
Nicholas Buffinger (Reg No. 39,124)
Mark R. Carter (Reg No. 39,131)
Peng Chen (Reg No. 43,543)
Thomas Chuang (Reg No. 44,616)
Cara M. Coburn (Reg No. 46,631)
Raj S. Davé (Reg No. 42,465)
Stephen C. Durant (Reg No. 31,506)
David L. Fehrman (Reg No. 28,600)
Thomas George (Reg No. 45,740)

Debra J. Glaister (Reg No. 33,888)
Johney U. Han (Reg No. 45,565)
Alan S. Hodes (Reg No. 38,185)
Peter Hsieh (Reg No. 44,780)
Madeline I. Johnston (Reg No. 36,174)
Parisa Jorjani (Reg No. 46,813)
Richard C. Kim (Reg No. 40,046)
Kawai Lau (Reg No. 44,461)
Michael J. Mauriel (Reg No. 44,226)
Philip A. Morin (Reg No. P-45,926)
Martin M. Noonan (Reg No. 44,264)
Paul J. Riley (Reg No. 38,596)
Terri Shieh-Newton (Reg No. 47,081)
Kevin R. Spivak (Reg No. 43,148)
Michael R. Ward (Reg No. 38,651)
Todd W. Wight (Reg No. 45,218)
David T. Yang (Reg No. 44,415)
George C. Yu (Reg No. 44,418)

Kenneth R. Glick (Reg No. 28,612)
Douglas G. Hodder (Reg No. 41,840)
Charles D. Holland (Reg No. 35,196)
Wayne Jaeschke, Jr. (Reg No. 38,503)
Richard D. Jordan (Reg No. 33,519)
Ararat Kapouytian (Reg No. 40,044)
Cameron A. King (Reg No. 41,897)
Rimas T. Lukas (Reg No. 46,451)
Gladys H. Monroy (Reg No. 32,430)
Kate H. Murashige (Reg No. 29,959)
Catherine M. Polizzi (Reg No. 40,130)
Debra A. Shetka (Reg No. 33,309)
Rebecca Shortle (Reg No. 47,083)
Stanley H. Thompson (Reg No. 45,160)
E. Thomas Wheelock (Reg No. 28,825)
Frank Wu (Reg No. 41,386)
Peter J. Yim (Reg No. 44,417)
Karen R. Zachow (Reg No. 46,332)

all of Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018, telephone (650) 813-5600, to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71 provided that if any one of said attorneys or agents ceases being affiliated with the law firm of Morrison & Foerster as partner, employee or of counsel, such attorney's or agent's appointment as attorney or agent and all powers derived therefrom shall terminate on the date such attorney or agent ceases being so affiliated.


Please direct all written communications relative to this application to:

Madeline I. Johnston
Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018

Please direct all telephone communications to Madeline I. Johnston at (650) 813-5840.

LA JOLLA PHARMACEUTICAL COMPANY
a Delaware corporation

Dated: July 20, 2001

A handwritten signature in cursive script, appearing to read "Andrew Wiseman", written over a horizontal line.

Name: Andrew Wiseman

Title: Director of Business Development

Address: 6455 Nancy Ridge Drive
San Diego, CA 92121



RECEIVED

AUG 01 2001 PTO/SB/96 (10-92)

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

Docket No. 252312005704

TECH CENTER 1600/2900

In the application of: Stephen M. COUTTS et al.
Serial No.: 09/752,533
Filed: December 29, 2000
For: CONJUGATES OF CHEMICALLY DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND BIOLOGICALLY ACTIVE MOLECULES (AS AMENDED)

La Jolla Pharmaceutical Company, a Delaware corporation, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 6827, Frame 0662, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:

1. From : *
To : *

The document was recorded in the Patent and Trademark Office at Reel *, Frame *, or for which a copy thereof is attached.

2. From : *
To : *

The document was recorded in the Patent and Trademark Office at Reel *, Frame *, or for which a copy thereof is attached.

3. From : *
To : *

The document was recorded in the Patent and Trademark Office at Reel *, Frame *, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: July 20, 2001


Name: Andrew Wiseman

Title: Director of Business Development